Mild Cognitive Impairment Market

Market Overview:

The 7 major mild cognitive impairment markets are expected to exhibit a CAGR of 4.02% during 2024-2034.

The mild cognitive impairment market has been comprehensively analyzed in IMARC's new report titled "Mild Cognitive Impairment Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mild cognitive impairment refers to a condition characterized by noticeable cognitive changes that are greater than expected for an individual's age and education level but do not significantly interfere with daily functioning. Some of the common symptoms are memory difficulties like forgetfulness of recent events or important information, challenges with attention and concentration, problems with language, including word-finding difficulties or trouble expressing thoughts, etc. Additionally, individuals suffering from the ailment may experience a reduced ability to make decisions or solve problems and mild impairments in visuospatial skills, such as getting lost in familiar surroundings. Diagnosing mild cognitive impairment involves a comprehensive evaluation that includes a medical history assessment, cognitive testing, and clinical examination. Healthcare professionals, such as neurologists, use standardized cognitive assessments to evaluate various cognitive domains, including memory, attention, language, executive functions, etc. In addition to this, they may consider the input of the patient and their close contacts to assess changes in cognitive abilities and daily functioning. Numerous imaging tests, such as magnetic resonance imaging (MRI), may be conducted to rule out other underlying causes or conditions.

The increasing cases of neurodegenerative conditions, including Alzheimer's disease and Parkinson's disease, which result in the progressive degeneration of neurons in specific areas of the brain, are primarily driving the mild cognitive impairment market. In addition to this, the rising prevalence of various associated risk factors, such as mental health disorders like depression and anxiety, certain vascular diseases that affect blood flow to the brain, lack of mental and social stimulation, advancing age, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of novel medications, including cholinesterase inhibitors and memantine, which enhance neurotransmitter activity and help to manage memory and thinking problems, is further bolstering the market growth. Apart from this, the inflating application of cognitive rehabilitation programs that involve structured interventions, such as memory training, attention exercises, problem-solving tasks, etc., for improving specific cognitive abilities is acting as another significant growth-inducing factor. Additionally, the emerging popularity of non-invasive brain stimulation techniques, including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), since they facilitate synaptic changes and enhance neural plasticity, thereby leading to improved cognitive function, is expected to drive the mild cognitive impairment market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the mild cognitive impairment market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for mild cognitive impairment and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mild cognitive impairment market in any manner.

Recent Developments:

• In April 2024, Sage Therapeutics, Inc. published topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the experimental oral medication dalzanemdor (SAGE-718) in patients with mild cognitive impairment (MCI) in Parkinson's disease (PD). SAGE-718 was generally well accepted, with no new safety signs detected.

Key Highlights:

• Mild cognitive impairment is an early indication of Alzheimer's disease in almost half of cases, progressing to dementia at a rate of 10% to 15% per year.
• The global prevalence of MCI in community-dwelling people aged 50 and older was noted to be 15.56%.
• The prevalence rates of amnestic and non-amnestic MCI were 10.03% and 8.72%, respectively.
• A new study found that a diagnosis of atrial fibrillation (AF) was associated with a 45% greater risk of mild cognitive impairment in a cohort of 4.3 million people in the UK.
• MCI is more prevalent in elderly women than in males.

Drugs:

Levetiracetam ER (AGB-101) is being developed as a treatment for amnestic mild cognitive impairment caused by Alzheimer's dementia and psychosis. The medication candidate is a once-daily extended-release capsule and tablet formulation of levetiracetam taken orally. It works by targeting the synaptic vesicle protein (SV2A) ligand.

Dalzanemdor (SAGE-718), a first-in-class experimental NMDA receptor positive allosteric modulator (PAM), is being developed as an oral medication for cognitive diseases caused by NMDA receptor malfunction, such as Huntington's disease (HD) and Alzheimer's disease (AD). Sage is developing a clinical program for dalzanemdor (SAGE-718), with many ongoing placebo-controlled Phase 2 trials in multiple disease categories, including its prospective lead indication, cognitive impairment associated with HD, and cognitive impairment in AD.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the mild cognitive impairment market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the mild cognitive impairment market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current mild cognitive impairment marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the mild cognitive impairment market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the mild cognitive impairment market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the mild cognitive impairment market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of mild cognitive impairment across the seven major markets?
• What is the number of prevalent cases (2018-2034) of mild cognitive impairment by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of mild cognitive impairment by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with mild cognitive impairment across the seven major markets?
• What is the size of the mild cognitive impairment patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of mild cognitive impairment?
• What will be the growth rate of patients across the seven major markets?
   

Mild Cognitive Impairment: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for mild cognitive impairment drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mild cognitive impairment market?
• What are the key regulatory events related to the mild cognitive impairment market?
• What is the structure of clinical trial landscape by status related to the mild cognitive impairment market?
• What is the structure of clinical trial landscape by phase related to the mild cognitive impairment market?
• What is the structure of clinical trial landscape by route of administration related to the mild cognitive impairment market?